Cardioprotective and Hepatoprotective Potential of Silymarin in Paracetamol-Induced Oxidative Stress
Pharmaceutics · 09.04.2024 · 16 (4) · 520
DOI: 10.3390/pharmaceutics16040520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 09.04.2024. Verfasst von Bogdan Okiljević und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Dedinje Cardiovascular Institute, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pokrajinski Sekretarijat za Nauku i Tehnološki Razvoj.
Abstract (Originalsprache)
Silymarin, derived from Silybum marianum, has been used in traditional medicine for various ailments. In this study, the cardioprotective and hepatoprotective effects of silymarin against paracetamol-induced oxidative stress were examined in 28 male Swiss Webster mice, divided into four groups and treated for 7 days (via the oral route) with (a) saline 1 mL/kg (control group), (b) saline 1 mL/kg + single dose of paracetamol 110 mg/kg on the 7th day; (c) silymarin 50 mg/kg; and (d) silymarin 50 mg/kg + single dose of paracetamol 110 mg/kg on the 7th day. In vitro and in vivo antioxidant activity together with liver enzyme activity were evaluated. Histopathological and immunohistochemical assessment was performed. Silymarin mitigated paracetamol-induced liver injury by reducing oxidative stress markers such as lipid peroxidation and restoring antioxidant enzyme activity. Silymarin treatment resulted in a significant decrease in liver enzyme levels. Reduced necrosis and inflammatory infiltrate in liver tissues of silymarin-treated groups were detected as well. Immunohistochemical analysis demonstrated reduced expression of inflammatory markers (COX2, iNOS) and oxidative stress marker (SOD2) in the liver tissues of the silymarin-treated groups. Similar trends were observed in cardiac tissue. These results suggest that silymarin exerts potent hepatoprotective and cardioprotective effects against paracetamol-induced oxidative stress, making it a promising therapeutic agent for liver and heart diseases associated with oxidative damage.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiac Surgery, Dedinje Cardiovascular Institute, 11000 Belgrade, Serbia.
- Department of Pharmacology, Toxicology, and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
- Clinic of Urology, Clinical Center of Vojvodina, 21000 Novi Sad, Serbia.
- Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
- Department of Histology and Embryology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
- Faculty of Technology, University of Novi Sad, 21000 Novi Sad, Serbia.
ORCID-Profile: Bogdan Okiljević, Nikola Martić, Srđan Govedarica, Bojana Andrejić Višnjić, Milana Bosanac, Branimir Pavlić
Förderung
- Pokrajinski Sekretarijat za Nauku i Tehnološki Razvoj
Zitieren
APA
Okiljević, B., Martić, N., Govedarica, S., Andrejić Višnjić, B., Bosanac, M., Baljak, J., Pavlić, B., Milanović, I., & Rašković, A. (2024). Cardioprotective and Hepatoprotective Potential of Silymarin in Paracetamol-Induced Oxidative Stress. Pharmaceutics, 16(4), 520. https://doi.org/10.3390/pharmaceutics16040520
Vancouver
Okiljević B, Martić N, Govedarica S, Andrejić Višnjić B, Bosanac M, Baljak J, et al. Cardioprotective and Hepatoprotective Potential of Silymarin in Paracetamol-Induced Oxidative Stress. Pharmaceutics. 2024;16(4):520. doi:10.3390/pharmaceutics16040520
BibTeX
@article{Okiljevi2024,
author = {Okiljević, Bogdan and Martić, Nikola and Govedarica, Srđan and Andrejić Višnjić, Bojana and Bosanac, Milana and Baljak, Jovan and Pavlić, Branimir and Milanović, Isidora and Rašković, Aleksandar},
title = {Cardioprotective and Hepatoprotective Potential of Silymarin in Paracetamol-Induced Oxidative Stress},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {4},
pages = {520},
doi = {10.3390/pharmaceutics16040520}
}
EUVIMED